Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.46 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13688853 | 0.94 | HSD11B1 (0.50) | EPHX2HSD11B1HSD11B2 | |
| SCHEMBL1770089 | 0.77 | ALDH1A1 (0.51) | EPHX2HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1770009 | 0.76 | PPARD (0.45) | HSD11B1SMN1; SMN2 | |
| SCHEMBL20808089 | 0.75 | MRGPRX4 (0.56) | MRGPRX4SMN1; SMN2LIPE | |
| SCHEMBL1770025 | 0.75 | HSD11B1 (0.39) | EPHX2HSD11B1HSD11B2SMN1; SMN2 | |
| SCHEMBL6084864 | 0.71 | HSP90AA1 (0.50) | EPHX2HSD11B1HSP90AA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13333321 | 0.70 | ALDH1A1 (0.48) | HSD11B1HSP90AA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1769934 | 0.70 | HSD11B1 (0.61) | HSD11B1HSP90AA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1770383 | 0.69 | ALDH1A1 (0.53) | HSD11B1HSP90AA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10848575 | 0.69 | MRGPRX4 (0.49) | MRGPRX4SMN1; SMN2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2257528-A2 | 1 IBETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106817-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | EPHX2 292/4885HSD11B1 1/4885HSD11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.